Evaluation of the prognostic value of serum soluble CD 44 in patients with breast cancer

Cancer Investigation

Volumn 17, Issue 8, 1999, Pages 581-585

  Sheen Chen, Shyr Ming ^a   Chen, Wei Jen ^b   Eng, Hock Liew ^b   Sheen, Chih Chi ^b   Chou, Fong Fu ^b   Cheng, Yu Fan ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

HERMES ANTIGEN;

ADULT; AGED; ANTIGEN DETECTION; ARTICLE; BREAST CANCER; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PLOIDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL;

EID: 0032696397     PISSN: 07357907     EISSN: None     Source Type: Journal    
DOI: 10.3109/07357909909032843     Document Type: Article

References (28)

1. Butcher EC: The regulation of lymphocyte traffic. Curr Top Microbiol Immunol 128:85-122, 1986.
2. Haynes BF, Telen MJ, Hole LP, et al: CD 44 - a molecule involved in leukocyte adherence and T-cell activation. Immun Today 10:423-438, 1989.
3. Arch R, Wirth K, Hofmann M, et al: Participation in normal immune responses of a metastases-inducing splice variant of CD 44. Science 257:682-685, 1992.
4. Gunther U, Hofmann M, Rudy W, et al: A new variant of glycoprotein CD 44 confers metastatic potential to rat carcinoma cell. Cell 65:13-24, 1991.
5. Miya KL, Medina KL, Hayasi SI, et al: Monoclonal antibodies to Pgp-1/CD 44 block lymphohematopoiesis in long term bone marrow cultures. J Exp Med 171:477-488, 1990.
6. Screaton GR, Bell MV, Jackson DG, et al: Genomic structure of DNA encoding the lymphocyte homing receptor CD 44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 89:12160-12164, 1992.
7. Denning SM, Le PT, Singer KH, et al: Antibodies against the CD 44 P80, lymphocyte homing receptor molecule augment human peripheral blood T cell activation. J Immunol 144:7-15, 1990.
8. Webb DSA, Shimizu Y, Van Seventer GA, et al: LAF-3,CD 44 and CD45: physiologic triggers of human monocyte TNF and IL-1 release. Science 249:1295-1297, 1990.
9. Jacobson K, Odell D, Holifield B, et al: Redistribution of a major cell surface glycoprotein during cell movement. J Cell Biol 99: 1613-1623, 1984.
10. Nicolson GL: Tumor cell instability, diversification and progression to the metastatic phenotype: from oncogene to oncofetal expression. Cancer Res 47:1473-1487, 1987.
11. Hart IR, Goode NT, Wilson RE: Molecular aspects of the metastatic cascade. Biochem Biophys Acta 989:65-84, 1989.
12. Smith CW, Patton JG, Nadal Ginard B: Alternative splicing in the control of gene expression. 23:527-577, 1989.
13. Mulder J-WR, Kruyt PM, Sew Nath, et al: Colorectal cancer prognosis and expression of exon-v6-containing CD 44 proteins. Lancet 344:1470-1472, 1994.
14. Kainz C, Kohlberger P, Tempfer C, et al: Prognostic value of CD 44 splice variants in human stage III cervical cancer. Eur J Cancer 31A:1706-1709, 1995.
15. Kaufmann M, Heider KH, Sinn HP, et al: CD 44 variant exon epitopes in primary breast cancer and length of survival. Lancet 345:615-619, 1995.
16. Kuppner MC, Meir EV, Gauthier TH, et al: Differential expression of the CD 44 molecules in human brain tumors. Int J Cancer 50:572-577, 1992.
17. Ristamaki R, Joensuu H, Salmi M, et al: Serum CD 44 in malignant lymphoma: an association with treatment response. Blood 84:238-243, 1994.
18. Guo YJ, Liu G, Wang X, et al: Potential use of soluble CD 44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 54:422-426, 1994.
19. Kainz C, Tempfer C, Winkler S, et al: Serum CD 44 splice variants in cervical cancer patients. Cancer Lett 90:231-234, 1995.
20. Bloom HJG, Richardson WW: Histological grading and prognosis in breast cancer. Br J Cancer 11:359-377, 1957.
21. The World Health Organization. Histological typing of breast tumor. Am J Clin Pathol 78:806-816, 1982.
22. Staging for carcinoma of the breast. In: Manual for Staging of Cancer, 3rd ed, edited by Beahrs, D Henson, R Hutter, M Myers, Philadelphia, J.B. Lippincott, 1988, pp. 145-150.
23. Sheen-Chen SM, Chen WJ , Eng HL, et al: Serum-soluble interleukin-2 receptor concentrations in patients with breast cancer: a preliminary report. Chang Gung Med J 21:133-138, 1998.
24. Hedley DW, Friedlander ML, Taylor IW, et al: Method for analysis of cellular DNA of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31:1333-1335, 1983.
25. Gunthert U, Hofmann M, Rudy W, et al: A new variant of glycoprotein CD 44 confers metastatic potential to rat carcinoma cell. Cell 65:13-24, 1991.
26. Underhill C: CD 44: the hyaluronan receptor. J Cell Sci 103:293-298, 1992.
27. Friedrichs K, Franke F, Lisboa BW, et al: CD 44 isoforms correlate with cellular differentiation but not with prognosis in human breast cancer. Cancer Res 55:5424-5433, 1995.
28. Tempfer C, Losch A, Heinzl H, et al: Prognostic value of immunohistochemically detected CD 44 isoforms CD 44 V5, CD 44 V6 and CD 44 V7-8 in human breast cancer. Eur J Cancer 32A: 2023-2025, 1996.